ストックスクリーナーアプリを入手
0.3501
52.37%
-0.3849
Avenue Therapeutics Inc (ATXI) 最新ニュース
Century Therapeutics (NASDAQ:IPSC) Stock Rating Upgraded by Wall Street Zen - MarketBeat
Pacific Heights Asset Management LLC Raises Stake in Structure Therapeutics Inc. Sponsored ADR $GPCR - MarketBeat
TG Therapeutics, Inc. (NASDAQ:TGTX) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
CytomX Therapeutics, Inc. (NASDAQ:CTMX) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Fate Therapeutics (NASDAQ:FATE) Stock Price Crosses Above 50-Day Moving AverageHere's What Happened - MarketBeat
Maze Therapeutics (NASDAQ:MAZE) Cut to "Sell" at Wall Street Zen - MarketBeat
More cash flows into biotechs during conference week: Finance Report - BioCentury
Aptevo Therapeutics (NASDAQ: APVO) seeks OK for $60M SEPA share sales - Stock Titan
Market Recap: Can Ernexa Therapeutics Inc continue delivering strong returnsJuly 2025 PostEarnings & Low Risk High Reward Ideas - baoquankhu1.vn
Avenue Therapeutics shareholders elect directors, ratify KPMG auditor - MSN
Early ZYCUBO treatment cut death risk nearly 80% in children with Menkes - Stock Titan
Capricor Therapeutics (NASDAQ:CAPR) Cut to Sell at Wall Street Zen - MarketBeat
Kyverna Therapeutics (NASDAQ:KYTX) Upgraded to "Hold" at Wall Street Zen - MarketBeat
Mersana Therapeutics (NASDAQ:MRSN) Upgraded at Wall Street Zen - MarketBeat
Karyopharm (NASDAQ: KPTI) plans big share authorization increase to fund 2026 trials - Stock Titan
Is PTC Therapeutics Inc. stock a defensive play in 20252025 Price Targets & Smart Investment Allocation Tips - Улправда
Capricor Therapeutics (NASDAQ:CAPR) Upgraded at Wall Street Zen - MarketBeat
PTC Therapeutics (NASDAQ:PTCT) Upgraded to Buy at Wall Street Zen - MarketBeat
Avenue Therapeutics Provides Regulatory Update on IV Tramadol and Other Corporate Updates - ADVFN
Fortress Biotech, Cyprium Therapeutics and Sentynl Therapeutics Announce CUTX-101, Copper Histidinate, Data to be Presented at 2022 American College of Medical Genetics Annual Clinical Genetics Meeting - ADVFN
Avenue Therapeutics (ATXI) investors reelect six directors and ratify KPMG for 2025 - Stock Titan
Axsome Therapeutics shares gain 1.4% premarket after FDA grants priority review for co's Alzheimer's agitation drug - marketscreener.com
FDA supports Axsome’s NDA submission for narcolepsy drug AXS-12 By Investing.com - Investing.com Australia
ATXI: All directors were elected and KPMG LLP was ratified as auditor for 2025 - TradingView — Track All Markets
ATXI: All director nominees were elected and KPMG LLP was ratified as auditor for 2025 - TradingView — Track All Markets
Esperion Therapeutics, Inc. (NASDAQ:ESPR) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Dyne Therapeutics (NASDAQ:DYN) Stock Rating Lowered by Wall Street Zen - MarketBeat
vTv Therapeutics (NASDAQ:VTVT) Upgraded at Wall Street Zen - MarketBeat
Vera Therapeutics (VERA) Stock Dips in Thin Post‑Christmas Trading as Wall Street Weighs FDA Filing, $300M Raise, and IgA Nephropathy Competition - TechStock²
NexImmune (NASDAQ:NEXI) versus Avenue Therapeutics (NASDAQ:ATXI) Head-To-Head Comparison - Defense World
The Philippines - AstraZeneca
Avenue Therapeutics, Inc.Common Stock (NQ: ATXI - FinancialContent
Form 424B3 Ovid Therapeutics Inc. - StreetInsider
Will Neumora Therapeutics Inc. stock benefit from AI adoptionOil Prices & Weekly Setup with High ROI Potential - Улправда
Axsome Therapeutics stock hits all-time high at 152.98 USD - Investing.com
Axsome Therapeutics stock hits all-time high at 152.98 USD By Investing.com - Investing.com Australia
Axsome Therapeutics (AXSM) Gets a Buy from Jefferies - The Globe and Mail
Avenue Therapeutics (ATXI) plans resale of 731,061 warrant-linked shares - Stock Titan
[RW] AVENUE THERAPEUTICS, INC. SEC Filing - Stock Titan
Fortress Biotech (Nasdaq: FBIO): FDA accepts Class 1 resubmission, CUTX-101 PDUFA Jan. 14, 2026 - Stock Titan
Spero Therapeutics (NASDAQ:SPRO) Upgraded to "Buy" at Wall Street Zen - MarketBeat
TG Therapeutics (NASDAQ:TGTX) Rating Increased to Buy at Wall Street Zen - MarketBeat
RBC Capital Sticks to Its Buy Rating for Axsome Therapeutics (AXSM) - The Globe and Mail
Sionna Therapeutics (NASDAQ:SION) Upgraded at Wall Street Zen - MarketBeat
Axsome Confident On Regulatory, Commercial Outlook for Alzheimer's Agitation Drug Candidate, RBC Says - marketscreener.com
Vera Therapeutics (VERA) Stock Outlook: December 11, 2025 Update on Public Offering, Atacicept BLA and Wall Street Targets - ts2.tech
Dyne Therapeutics Announces Pricing of Upsized $350.0 Million Public Offering of Common Stock - GlobeNewswire
Intellia Therapeutics (NASDAQ:NTLA) Stock Rating Upgraded by Wall Street Zen - MarketBeat
Avenue Therapeutics Inc. (ATXI) Stock Price | Live Quotes & Charts | OTO - StocksToTrade
Spero Therapeutics (NASDAQ:SPRO) Stock Rating Lowered by Wall Street Zen - MarketBeat
Rapport Therapeutics (NASDAQ:RAPP) Downgraded to Sell Rating by Wall Street Zen - MarketBeat
Avenue Therapeutics (NASDAQ: ATXI) 2025 proxy on director elections, KPMG audit and Fortress control - Stock Titan
Wall Street Analysts Think Mineralys Therapeutics, Inc. (MLYS) Could Surge 27.55%: Read This Before Placing a Bet - WV News
Axsome therapeutics CEO Tabuteau sells $11.6 million in shares By Investing.com - Investing.com India
Axsome therapeutics CEO Tabuteau sells $11.6 million in shares - Investing.com
Minerva jumps on phase III funding, leading neuro stocks - BioWorld MedTech
Wall Street Analysts Believe Enliven Therapeutics, Inc. (ELVN) Could Rally 101.26%: Here's is How to Trade - WV News
Akebia Therapeutics (NASDAQ:AKBA) Downgraded by Wall Street Zen to "Buy" - MarketBeat
Protagenic Therapeutics Announces Receipt of Nasdaq Non-Compliance Notice - USA Today
Esperion Therapeutics Stock Hits Near 1-Year High As Wall Street Sees Strong Risk-Reward Play On Demand For Cholesterol Drug - Stocktwits
16.27%
0.47%
大文字化:
|
ボリューム (24 時間):